{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:05:00Z","timestamp":1792184700381,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T00:00:00Z","timestamp":1310083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00198-011-1658-2","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T19:54:38Z","timestamp":1310068478000},"page":"285-294","source":"Crossref","is-referenced-by-count":55,"title":["Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists"],"prefix":"10.1007","volume":"23","author":[{"given":"L. A.","family":"Bradbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. H.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. G. G.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"1658_CR1","first-page":"293","volume":"46","author":"B Sykes","year":"1990","unstructured":"Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C et al (1990) Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 46:293\u2013307","journal-title":"Am J Hum Genet"},{"key":"1658_CR2","first-page":"638","volume":"55","author":"MC Willing","year":"1994","unstructured":"Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL et al (1994) Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 55:638\u2013647","journal-title":"Am J Hum Genet"},{"key":"1658_CR3","first-page":"508","volume":"51","author":"MC Willing","year":"1992","unstructured":"Willing MC, Pruchno CJ, Atkinson M, Byers PH (1992) Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. Am J Hum Genet 51:508\u2013515","journal-title":"Am J Hum Genet"},{"key":"1658_CR4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18388\/abp.2002_3802","volume":"49","author":"A Gajko-Galicka","year":"2002","unstructured":"Gajko-Galicka A (2002) Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol 49:433\u2013441","journal-title":"Acta Biochim Pol"},{"key":"1658_CR5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1359\/jbmr.091109","volume":"25","author":"F Rauch","year":"2010","unstructured":"Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367\u20131374","journal-title":"J Bone Miner Res"},{"key":"1658_CR6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"1658_CR7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","volume":"18","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610\u2013614","journal-title":"J Bone Miner Res"},{"key":"1658_CR8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","volume":"88","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986\u2013992","journal-title":"J Clin Endocrinol Metab"},{"key":"1658_CR9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","volume":"111","author":"MJ Falk","year":"2003","unstructured":"Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D et al (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573\u2013578","journal-title":"Pediatrics"},{"key":"1658_CR10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1297-319X(02)00434-7","volume":"69","author":"F Giraud","year":"2002","unstructured":"Giraud F, Meunier PJ (2002) Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 69:486\u2013490","journal-title":"Joint Bone Spine"},{"key":"1658_CR11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE et al (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977\u2013986","journal-title":"J Bone Miner Res"},{"key":"1658_CR12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M et al (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758\u2013763","journal-title":"J Bone Miner Res"},{"key":"1658_CR13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132\u2013140","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1658_CR14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, Munns C, Land C, Cheung M, Glorieux F (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24(7):1282\u20131289","journal-title":"J Bone Miner Res"},{"key":"1658_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355\u2013364","journal-title":"J Clin Endocrinol Metab"},{"key":"1658_CR16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, Fracassi E, Braga V et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126\u2013130","journal-title":"J Bone Miner Res"},{"key":"1658_CR17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","volume":"21","author":"G Chevrel","year":"2006","unstructured":"Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300\u2013306","journal-title":"J Bone Miner Res"},{"key":"1658_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.endonu.2010.03.017","volume":"57","author":"I Pavon de Paz","year":"2010","unstructured":"Pavon de Paz I, Iglesias Bolanos P, Duran Martinez M, Olivar Roldan J, Guijarro De Armas G et al (2010) Effects of zoledronic acid in adults with osteogenesis imperfecta. Endocrinol Nutr 57:245\u2013250","journal-title":"Endocrinol Nutr"},{"key":"1658_CR19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","volume":"72","author":"JR Shapiro","year":"2003","unstructured":"Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R et al (2003) The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72:103\u2013112","journal-title":"Calcif Tissue Int"},{"key":"1658_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1875-9572(09)60002-4","volume":"49","author":"HY Lin","year":"2008","unstructured":"Lin HY, Lin SP, Chuang CK, Chen MR, Chang CY (2008) Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta. Pediatr neonatol 49:161\u2013165","journal-title":"Pediatr neonatol"},{"key":"1658_CR21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5694\/j.1326-5377.2009.tb02421.x","volume":"190","author":"KM Sanders","year":"2009","unstructured":"Sanders KM, Nowson CA, Kotowicz MA, Briffa K, Devine A et al (2009) Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. Med J Aust 190:316\u2013320","journal-title":"Med J Aust"},{"key":"1658_CR22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","volume":"87","author":"JR Shapiro","year":"2010","unstructured":"Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87:120\u2013129","journal-title":"Calcif Tissue Int"},{"key":"1658_CR23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M et al (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427\u20131431","journal-title":"Lancet"},{"key":"1658_CR24","volume-title":"Statistical power analysis for the behavioural sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioural sciences. Lawrence Erlbaum Associates, Hillsdale"},{"key":"1658_CR25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00198-005-1945-x","volume":"16","author":"S Boonen","year":"2005","unstructured":"Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291\u20131298","journal-title":"Osteoporos Int"},{"key":"1658_CR26","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","volume":"310","author":"CR Paterson","year":"1984","unstructured":"Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694\u20131696","journal-title":"N Engl J Med"},{"key":"1658_CR27","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D et al (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786\u2013791","journal-title":"J Pediatr Orthop"},{"key":"1658_CR28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1658_CR29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, Hochberg M, Ott S et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"1658_CR30","unstructured":"Ruston D, Hoare J, Henderson L, Gregory J, Bates C et al (2004) The National Diet and Nutrition Survey: adults aged 19 to 64\u00a0years. In: Office for National Statistics MRCHNR at FSA (ed). Office of National Statistics, London"},{"key":"1658_CR31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","volume":"34","author":"V Braga","year":"2004","unstructured":"Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E et al (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone 34:1013\u20131016","journal-title":"Bone"},{"key":"1658_CR32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1373\/clinchem.2006.083055","volume":"53","author":"T Cundy","year":"2007","unstructured":"Cundy T, Horne A, Bolland M, Gamble G, Davidson J (2007) Bone formation markers in adults with mild osteogenesis imperfecta. Clin Chem 53:1109\u20131114","journal-title":"Clin Chem"},{"key":"1658_CR33","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.85.5.1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J et al (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3\u00a0years of age. J Clin Endocrinol Metab 85:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"1658_CR34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jbspin.2004.09.005","volume":"72","author":"V Vyskocil","year":"2005","unstructured":"Vyskocil V, Pikner R, Kutilek S (2005) Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72:416\u2013423","journal-title":"Joint Bone Spine"},{"key":"1658_CR35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","volume":"25","author":"N Bishop","year":"2010","unstructured":"Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25:32\u201340","journal-title":"J Bone Miner Res"},{"key":"1658_CR36","doi-asserted-by":"crossref","unstructured":"Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev: CD005088","DOI":"10.1002\/14651858.CD005088.pub2"},{"key":"1658_CR37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"1658_CR38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293\u20131299","journal-title":"J Clin Invest"},{"key":"1658_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","volume":"22","author":"JJ Brown","year":"2009","unstructured":"Brown JJ, Zacharin MR (2009) Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 22:55\u201363","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1658-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1658-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1658-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T15:06:08Z","timestamp":1712588768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1658-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1658-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,8]]}}}